NUVB
NYSE · Pharmaceuticals
Nuvation Bio Inc
$4.16
-0.03 (-0.72%)
Financial Highlights (FY 2026)
Revenue
57.46M
Net Income
-186,873,146
Gross Margin
85.2%
Profit Margin
-325.3%
Rev Growth
—
D/E Ratio
0.68
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 85.2% | 30.1% | 30.1% | 30.1% |
| Operating Margin | -338.7% | 16.4% | 16.5% | 16.7% |
| Profit Margin | -325.3% | 18.1% | 17.1% | 14.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 57.46M | 781.90M | 798.00M | 765.15M |
| Gross Profit | 48.96M | 235.01M | 239.85M | 229.97M |
| Operating Income | -194,615,776 | 127.95M | 131.99M | 127.76M |
| Net Income | -186,873,146 | 141.36M | 136.11M | 112.82M |
| Gross Margin | 85.2% | 30.1% | 30.1% | 30.1% |
| Operating Margin | -338.7% | 16.4% | 16.5% | 16.7% |
| Profit Margin | -325.3% | 18.1% | 17.1% | 14.7% |
| Rev Growth | — | +23.6% | -6.7% | +21.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 298.98M | 905.43M | 817.23M | 875.20M |
| Total Equity | 438.71M | 1.08B | 1.14B | 1.08B |
| D/E Ratio | 0.68 | 0.84 | 0.71 | 0.81 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -192,986,839 | 195.91M | 227.47M | 197.01M |
| Free Cash Flow | — | 85.45M | 83.04M | 102.29M |